SCHEMBL5074408

SCHEMBL5074408

CCOC(=O)c1nc(COC)oc1NC(=O)C1COc2ccccc2O1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 6/20 0.62
TSHR P16473 4/20 0.62
NPSR1 Q6W5P4 3/20 0.62
KDM4E B2RXH2 2/20 0.55
LMNA P02545 1/20 0.55
SMN1; SMN2 Q16637 6/20 0.54
ALDH1A1 P00352 4/20 0.54
HPGD P15428 1/20 0.53
HTT P42858 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
NPC1 O15118 8/20 0.51
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
BLM P54132 1/20 0.50
RAB9A P51151 7/20 0.49
MAPT P10636 2/20 0.49
TP53 P04637 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
ALOX15 P16050 1/20 0.49
HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4960141 0.89 POLB (0.53) L3MBTL1TSHRNPSR1KDM4ESMN1; SMN2
SCHEMBL4957699 0.84 L3MBTL1 (0.60) L3MBTL1TSHRNPSR1KDM4ELMNA
SCHEMBL14522815 0.83 TP53 (0.48) L3MBTL1TSHRNPSR1MAPTTP53
SCHEMBL4960279 0.82 L3MBTL1 (0.58) L3MBTL1TSHRNPSR1KDM4ELMNA
SCHEMBL4961142 0.78 MAPT (0.48) L3MBTL1TSHRNPSR1KDM4ELMNA
SCHEMBL4959414 0.75 KDM4E (0.64) L3MBTL1TSHRNPSR1KDM4ELMNA
SCHEMBL4958289 0.73 KDM4E (0.61) L3MBTL1TSHRNPSR1KDM4ELMNA
SCHEMBL4508777 0.70 L3MBTL1 (0.66) L3MBTL1TSHRNPSR1KDM4ELMNA
SCHEMBL612174 0.70 TSHR (0.63) L3MBTL1TSHRNPSR1KDM4ELMNA
SCHEMBL13779304 0.68 NPC1 (1.00) L3MBTL1TSHRNPSR1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312291-A1 Heterocyclic Gaba-b Modulators ASTRAZENECA AB (SE) 2008-12-18 US claimed
US-20080312291-A1 Heterocyclic Gaba-b Modulators ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312291-A1 Heterocyclic Gaba-b Modulators ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312291-A1 Heterocyclic Gaba-b Modulators ASTRAZENECA AB (SE) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312291-A1 Heterocyclic Gaba-b Modulators GABBR1, GABBR2, GABRB1 L3MBTL1 3068/4885TSHR 114/4885NPSR1 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.